Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Yao, Yihong ^a   Higgs, Brandon W ^a   Richman, Laura ^a   White, Barbara ^a   Jallal, Bahija ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCLONAL ANTIBODY; SIFALIMUMAB; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; INTERFERON; TRANSCRIPTOME;

B LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; DNA FLANKING REGION; DRUG DOSE ESCALATION; ELECTROCONVULSIVE THERAPY; GENE OVEREXPRESSION; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RHEUMATIC DISEASE; SCORING SYSTEM; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BIOSYNTHESIS; BLOOD; CLASSIFICATION; DENDRITIC CELL; DOSE RESPONSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SKIN; STATISTICS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PROGNOSIS; RHEUMATIC DISEASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN; TRANSCRIPTOME;

EID: 79956263705     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2887     Document Type: Review

References (50)

1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for Referral and Management of systemic lupus erythematosus in adults. Arthritis Rheum 1999, 42:1785-1796. 10.1002/1529-0131(199909)42:9<1785::AID-ANR1 3.0.CO;2-#, 10513791.
2. Petri M. Long-term outcomes in lupus. Am J Managed Care 2001, 7:S480-S485.
3. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Rönnblom L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9:664-671. 10.1191/096120300674499064, 11199920.
4. Rönnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003, 5:68-75. 165035, 12718746, 10.1186/ar625.
5. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004, 20:539-550. 10.1016/S1074-7613(04)00108-6, 15142523.
6. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004, 16:801-807. 10.1016/j.coi.2004.09.014, 15511676.
7. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with clinical and serologic manifestations of systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1692-1697. 1755300, 15843451, 10.1136/ard.2004.033753.
8. Crow M. Interferon-α: a new target for therapy in systemic lupus erythematosus?. Arthritis Rheum 2003, 48:2396-2401. 10.1002/art.11226, 13130457.
9. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. 10.1056/NEJMoa021933, 14561795.
10. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006, 18:676-682. 10.1016/j.coi.2006.09.014, 17011763.
11. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008, 17:394-399. 10.1177/0961203308090020, 18490415.
12. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I Interferons (a/b) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336. 10.1146/annurev.immunol.23.021704.115843, 15771573.
13. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003, 171:2366-2373.
14. Biron CA. Interferons α and β as immune regulators - a new look. Immunity 2001, 14:661-664. 10.1016/S1074-7613(01)00154-6, 11420036.
15. Bussfeld D, Nain M, Hoffman P, Gemsa D, Sprenger H. Selective induction of the monocyte-attracting chemokines MCP-1 and IP-10 in vesicular stomatitis virus-infected human monocytes. J Interferon Cytokine Res 2000, 20:615-621. 10.1089/107999000414781, 10926203.
16. Pogue SL, Preston BT, Stalder J, Bebbington CR, Cardarelli PM. The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J Interferon Cytokine Res 2004, 24:131-139. 10.1089/107999004322813372, 14980077.
17. Salazar-Mather TP, Hokeness KL. Calling in the troops: regulation of inflammatory cell trafficking through innate cytokine/chemokine networks. Viral Immunol 2003, 16:291-306. 10.1089/088282403322396109, 14583145.
18. Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis 2008, 66:176-183.
19. Sigurdsson S, Göring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, Eloranta ML, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jönsen A, Truedsson L, Barnes BJ, Alm G, Rönnblom L, Syvänen AC. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881. 10.1093/hmg/ddm359, 18063667.
20. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005, 24:178-181. 10.1007/s10067-004-1024-2, 15565395.
21. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000, 43:1431-1442. 10.1002/1529-0131(200007)43:7<1431::AID-ANR3 3.0.CO;2-E, 10902743.
22. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov F. IFNα induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174:2499-2506.
23. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulis AN. Type I interferon receptor deficiency reduces lupuslike disease in NZB mice. J Exp Med 2003, 197:777-788. 2193854, 12642605, 10.1084/jem.20021996.
24. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, Gallo RC, Koutouzov S. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009, 106:5294-5299. 2654395, 19279210, 10.1073/pnas.0900615106.
25. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
26. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324. 2758310, 19738166, 10.1093/jnci/djp280.
27. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
28. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
29. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 151388, 12604793, 10.1073/pnas.0337679100.
30. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 2193846, 12642603, 10.1084/jem.20021553.
31. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4:177-186. 10.1038/sj.gene.6363966, 12700592.
32. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3958-3967. 10.1002/art.20798, 15593221.
33. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
34. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962. 10.1002/art.22044, 16947629.
35. Yao Y, Higgs BW, Morehouse C, de los Reyes M, Brohawn P, Trigona W, White W, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Human Genomics Proteomics 2008, 2009:article 374312. doi:10.4061/2009/374312..
36. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Rönnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490. 10.1191/096120301678416042, 11480846.
37. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243. 1850412, 11438470.
38. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of IFN-α/β-inducible genes and downstream effect in a phase i trial of an anti-IFN-α monoclonal antibody in SLE. Arthritis Rheum 2009, 60:1785-1796. 10.1002/art.24557, 19479852.
39. Okamoto H, Katsumata Y, Nishimura K, Kamatani N. Interferon-inducible protein 10/CXCL10 is increased in cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004, 50:3731-3732. 10.1002/art.20598, 15529358.
40. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:1579-1588. 10.1002/art.22578, 17469140.
41. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006, 54:1906-1916. 10.1002/art.21890, 16736505.
42. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792. 2443782, 17968926, 10.1002/art.22928.
43. Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66:1008-1014. 10.1136/ard.2006.063412, 17223656, 1954704.
44. Båve U, Nordmark G, Lövgren T, Rönnelid J, Cajander S, Eloranta ML, Alm GV, Rönnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195. 10.1002/art.20998, 15818675.
45. Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:e12-e18. 10.1016/j.tripleo.2008.09.015, 19101478.
46. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz SM. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008, 58:1465-1474. 10.1002/art.23451, 18438864.
47. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678. 10.1002/ana.20464, 15852401.
48. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324. 218756, 14530402, 10.1073/pnas.1635114100.
49. Wallace DJ, Petri M, Olsen N, Kirou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematous [abstract 1325]. Arthritis Rheum 2007, 56:S526-S527.
50. McBride JM, Wallace DJ, Yao Z, Morimoto A, Jiang J, Maciuca R, McLean I, Drappa J. Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of Rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE [abstract 2072]. Arthritis Rheum 2009, 60:S775-S776.